Children's charity sees demand for services triple
KidsAid, which is based in Northampton and works across the Midlands and south east of England, provides long-term, trauma-specialised therapeutic support to children.
In 2024-25 the charity worked with 495 children in comparison to 2021-21 when it supported 163 children.
Carla Managan, the clinical lead at the charity, said: "A lot of children never returned to school [after the pandemic], and selective mutism has risen too.
"It surrounds anxiety about going back to school – many of these children struggled in school before the pandemic, then their anxiety increased during the time schools closed."
The charity said it planned to deliver 4,500 therapy sessions to more than 500 children and families this year.
Mrs Managan said the charity's staff has more than tripled in size since the pandemic.
"During Covid, we had eight therapists and two staff members. Now there are 25 therapists and 10 staff members. We are expanding all the time," she said.
The charity said in 2024 more than 60% of referrals it received were due to children being exposed to abuse, either experiencing it directly or witnessing others being abused.
It costs KidsAid about £2,200 to provide 26 weeks of one-to-one therapy for a child.
The charity said it received no statutory or public health funding, instead its services were financed through a combination of community and corporate fundraising, grants from trusts and foundations and some families contributing to sessions.
KidsAid said it currently received an average of 50 unfunded referrals each month, children in crisis who need help, but whom the charity lacks the money to support.
It said it seeks contributions from schools or applies for grants to support these referrals, but due to an increase in demand it cannot always support every unfunded referral.
Melisha Pillay has been a foster carer for three years and she sought support from KidsAid for one of the children in her care.
The child was given art therapy in her school for a year to help her understand and learn about emotions.
Ms Pillay said: "The art therapy allowed her to just feel more comfortable and be able to access emotions sometimes through colour, pictures, movement."
The success of the therapy has led to the child being reunited with her dad, Ms Pillay said.
She added that the child was now able to "express the emotion of sadness when she felt sad, but then also able to understand that we can hold two emotions".
Follow Northamptonshire news on BBC Sounds, Facebook, Instagram and X.
More like this
Primary school pupils going for mental health gold
Primary school lessons to focus on mental health
Youth music project 'boosts mental wellbeing'
Related internet links
KidsAid
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Ketamine's Antidepressant Action May Depend on Opioid System
Activation of the body's opioid system may be required for ketamine's antidepressant effects, new research hinted. In a small study of adults with major depressive disorder, taking the opioid blocker naltrexone before a low-dose ketamine infusion both blunted the surge in glutamate — a key brain chemical linked to mood — and reduced ketamine's rapid antidepressant benefit the next day. 'These results suggest that opioid receptors help mediate ketamine's effects and that blocking opioid receptors may lessen ketamine's acute mood-lifting action,' lead researcher Luke Jelen, MBBS, clinical lecturer in psychiatry, King's College London, London, England, told Medscape Medical News . 'However, this was a small, mechanistic study, not a treatment trial, so there is no immediate indication to change clinical practice or avoid naltrexone. Larger, dedicated clinical studies are required before recommending any alteration to current protocols,' Jelen cautioned. The study was published online on July 24 in Nature Medicine . New Mechanistic Insights Ketamine's rapid-acting antidepressant effects are thought to work by transiently elevating glutamate in the anterior cingulate cortex and other frontal regions, setting off a cascade of plasticity-related pathways. Prior animal and small human studies have suggested that activating mu-opioid receptors might be necessary for ketamine's mood benefits. To investigate, Jelen and colleagues enrolled 26 adults with moderate-to-severe depression in a randomized double-blind crossover trial separated by 3 weeks. Participants received either oral placebo or 50 mg naltrexone 1 hour before receiving intravenous ketamine (0.5 mg/kg). During the first 30 minutes of each infusion, they measured brain glutamatergic activity in the anterior cingulate cortex using functional magnetic resonance spectroscopy. Depressive symptoms were measured before and 24 hours after infusion, when ketamine's antidepressant effects peak, using the Montgomery-Åsberg Depression Rating Scale (MADRS). Compared with placebo, pretreatment with a single 50-mg dose of oral naltrexone reduced the brain's glutamatergic response and dampened the average improvement on MADRS measured 24 hours later, the researchers observed. Specifically, the glutamate signal climbed significantly during ketamine when participants had taken placebo, but the rise was significantly smaller when they had taken naltrexone ( P = .029; Cohen's d = 0.34). 'We also identified a sex-related effect: The attenuating effect of naltrexone on glutamate activity appeared more pronounced in males with depression than in females with depression,' Jelen said. Alongside the attenuation of ketamine-induced glutamatergic activity, naltrexone pretreatment also led to less marked reductions in clinician-rated MADRS scores 24 hours after infusion — equating to a 28% attenuation in the main effect of ketamine ( P = .023), the researchers reported. Reductions in self-reported depressive measures were numerically lower in the presence of naltrexone than in the presence of placebo, but the differences were not statistically significant. 'The possibility of an opioid mechanism underlying the antidepressant mechanisms of ketamine has been a recent subject of considerable debate. Our study provides evidence that opioid system activation may contribute to the acute antidepressant effects of ketamine,' the authors wrote. Looking ahead, Jelen told Medscape Medical News , a larger, well-powered study should include a true placebo-infusion arm to disentangle naltrexone's effects on both ketamine and placebo responses. He also noted that adding PET imaging would directly quantify opioid-receptor engagement, and prespecified analyses by sex are essential, given the stronger glutamate-dampening effect observed in men. 'Understanding more about how ketamine works can lead to treatment being personalized for different people, which is vital for creating safe and effective treatments,' Jelen said.
Yahoo
3 hours ago
- Yahoo
Postcode lottery for Mounjaro, the 'King Kong' of weight loss jabs, with only eight NHS care boards providing treatment
Thousands of severely obese patients are facing severely delayed treatment with what's been called the 'King Kong' of weight loss jabs - because the NHS rollout has been mismanaged and underfunded, according to Sky News research. Mounjaro was supposed to be available through GP surgeries and other community services from 23 June under an agreement between NHS England and the National Institute for Health and Care Excellence (NICE), the body that provides guidance on the use of new drugs. But Freedom of Information requests by Sky News reveal a postcode lottery, with only eight of 42 NHS Integrated Care Boards (ICBs) in England telling us they were providing treatment to patients, and many of the rest unable to guarantee when it would be available. The research also shows that at least 19 had a cap on how many eligible patients they would treat in the first year. Dr Jonathan Hazlehurst, an specialist at University Hospitals Birmingham, said many patients were desperate for treatment - and Mounjaro may be a hopeful aid for those eligible. "Giving people open promises and setting them up for disappointment and failure is clearly grossly unfair," he said. "That's what the current system is doing." NICE said in December that the NHS should offer Mounjaro to patients with a BMI over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. It calculated from NHS England data that there were 97,500 patients who should be treated in the first year. But Dr Hazelhurst says NHS England has only provided funding for just over 22,000 patients. Read more: "It shows that there's a lack of political will to fund this adequately," he said. "NHS England says that obesity costs the NHS £11.4bn per annum as a pure NHS cost. "Yet we can't even afford to properly fund the rollout of a life-changing drug in year one. That just doesn't make any sense." Gary - who doesn't want his surname used - weighs 25 stone (158kg) and becomes severely out of breath after climbing only a few stairs. He is eligible for treatment with Mounjaro under the agreed NHS guidelines. But his surgery said "no" and told him it would be at least the autumn before the drug would be available in the Hampshire area. "They said to us that September would be the earliest they going to look at it and then the criteria might change, so there's no knowing if I'm going to get it," he said. "I was so excited when I read about this drug. If I had the drug and lost some weight, it could help me move around, it could help me go fishing again, all kinds of things. "It's not for vanity. It would be a life changer." There are 3.4 million people in England who would qualify for treatment under the NICE eligibility criteria. But NHS England has said it will take 12 years to assess and prescribe to those who need it. Dr Hazlehurst said there would never be such a slow rollout with a new cancer treatment - and yet, obesity also kills. "There's a huge amount of stigma that drives things to do with obesity care all across the system," he said. "The 'eat less, move more' nonsense doesn't help. "That is a really unhelpful, harmful and stigmatising approach, particularly in an age of effective treatment." Read more from Thomas Moore: A spokesperson for NHS England said it had "fully supported the rollout" of Mounjaro. They said: "We issued guidance and provided funding in March to all Integrated Care Boards to support treatment costs, enable scaling of services and provide wrap-around care, including digital support services."
Yahoo
4 hours ago
- Yahoo
Man suffers 'multiple injuries' after tripping on Keswick fell
A man who suffered 'multiple injuries' after tripping on Catbells near Keswick, has been rescued. Keswick Mountain Rescue Team (MRT) were deployed on Saturday, August 2 to assist a 63-year-old man who had tripped on the 'short scramble section' on Skelgill Bank, Catbells. Due to the trip, the man has suuffered cuts and abrasions and sustained possible rib and spinal damage. After arriving at the scene, the man was assessed by Keswick MRT and stretchered down to an awaiting North West Ambulance Service (NWAS) crew. Writing on social media, Keswick MRT said: "A 63-year-old man tripped on the short scramble section on Skelgill Bank, Catbells, sustaining cuts and abrasions to his head and bashing his shoulder and elbow. "With multiple injuries and the possibility of rib and spinal damage the man was given pain relief and packaged in a vacuum mattress before being stretchered down to an awaiting ambulance." The rescue operation included 11 team members from Keswick MRT and lasted nearly three hours.
